Selection and estimation in exploratory subgroup analyses a proposal

Similar documents
Discussion Meeting for MCP-Mod Qualification Opinion Request. Novartis 10 July 2013 EMA, London, UK

On the Utility of Subgroup Analyses in Confirmatory Clinical Trials

Risk Assessment Update: ARREST SCALES February 28, 2018 DRAFT

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON MISSING DATA

In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials

Decision Making in Confirmatory Multipopulation Tailoring Trials

Cochrane Pregnancy and Childbirth Group Methodological Guidelines

Modeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients

Implementation of estimands in Novo Nordisk

Methods for Addressing Selection Bias in Observational Studies

Lecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method

Constructing AFQT Scores that are Comparable Across the NLSY79 and the NLSY97. Joseph G. Altonji Prashant Bharadwaj Fabian Lange.

Supporting a Pediatric Investigational Plan for Everolimus - Defining the extrapolation plan

Safeguarding public health Subgroup Analyses: Important, Infuriating and Intractable

Keyzilen TM Program Update

A Latent Variable Approach for the Construction of Continuous Health Indicators

Reflection paper on assessment of cardiovascular risk of medicinal products for the treatment of cardiovascular and metabolic diseases Draft

ICH E9(R1) Technical Document. Estimands and Sensitivity Analysis in Clinical Trials STEP I TECHNICAL DOCUMENT TABLE OF CONTENTS

Statistics for Clinical Trials: Basics of Phase III Trial Design

UMbRELLA interim report Preparatory work

XARACOLL Phase 3 Results Webcast. MATRIX 1 and MATRIX 2 Clinical Trials May 25, 2016

Design and analysis of clinical trials

Detection of Differential Test Functioning (DTF) and Differential Item Functioning (DIF) in MCCQE Part II Using Logistic Models

PLS 506 Mark T. Imperial, Ph.D. Lecture Notes: Reliability & Validity

Chapter 23. Inference About Means. Copyright 2010 Pearson Education, Inc.

Possibilities and risks associated with directly moving from Phase I to Phase III: Adaptive designs and Co

A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY

Linear Regression in SAS

Multi-Stage Stratified Sampling for the Design of Large Scale Biometric Systems

EPI 200C Final, June 4 th, 2009 This exam includes 24 questions.

AP Statistics Exam Review: Strand 2: Sampling and Experimentation Date:

MMI 409 Spring 2009 Final Examination Gordon Bleil. 1. Is there a difference in depression as a function of group and drug?

CEU screening programme: Overview of common errors & good practice in Cochrane intervention reviews

(Regulatory) views on Biomarker defined Subgroups

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

AVOIDING BIAS AND RANDOM ERROR IN DATA ANALYSIS

Analysis of TB prevalence surveys

Evaluating Social Programs Course: Evaluation Glossary (Sources: 3ie and The World Bank)

European Federation of Statisticians in the Pharmaceutical Industry (EFSPI)

These results are supplied for informational purposes only.

Bayesian graphical models for combining multiple data sources, with applications in environmental epidemiology

Stat 13, Intro. to Statistical Methods for the Life and Health Sciences.

UvA-DARE (Digital Academic Repository) Statistical evaluation of binary measurement systems Erdmann, T.P. Link to publication

Population-adjusted treatment comparisons Overview and recommendations from the NICE Decision Support Unit

CONSORT 2010 checklist of information to include when reporting a randomised trial*

Summary of main challenges and future directions

Biostatistics Primer

EMA Workshop on Multiplicity Issues in Clinical Trials 16 November 2012, EMA, London, UK

PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH

Estimands and Sensitivity Analysis in Clinical Trials E9(R1)

Confidence in Sampling: Why Every Lawyer Needs to Know the Number 384. By John G. McCabe, M.A. and Justin C. Mary

95% 2.5% 2.5% +2SD 95% of data will 95% be within of data will 1.96 be within standard deviations 1.96 of sample mean

CLINICAL PROTOCOL DEVELOPMENT

Lec 02: Estimation & Hypothesis Testing in Animal Ecology

Business Statistics Probability

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials

Meta-analysis to compare combination therapies: A case study in kidney transplantation

Safeguarding public health CHMP's view on multiplicity; through assessment, advice and guidelines

Bayesian approaches to handling missing data: Practical Exercises

Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods

The Maximum Mean Difference

Two-stage Methods to Implement and Analyze the Biomarker-guided Clinical Trail Designs in the Presence of Biomarker Misclassification

Bayesian Joint Modelling of Benefit and Risk in Drug Development

Meta-analysis of few small studies in small populations and rare diseases

Indirect Treatment Comparison Without Network Meta-Analysis: Overview of Novel Techniques

Logistic Regression Predicting the Chances of Coronary Heart Disease. Multivariate Solutions

MS&E 226: Small Data

Assay Sensitivity.

Standard Errors and Uncertainty in Agentbased

SCHOOL OF MATHEMATICS AND STATISTICS

Trial designs fully integrating biomarker information for the evaluation of treatment-effect mechanisms in stratified medicine

Instrumental Variables Estimation: An Introduction

Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarkers detection and subgroup identification

Factor Analysis of Gulf War Illness: What Does It Add to Our Understanding of Possible Health Effects of Deployment?

Further data analysis topics

Incorporating Clinical Information into the Label

confirmatory clinical trials - The PMDA Perspective -

BIOSTATISTICAL METHODS

Internal & External Validity

Utilizing the items from the MDS-UPDRS score to increase drug effect detection power in de novo idiopathic Parkinson's disease patients

Process of Designing & Implementing a Research Project

Multiplicity Considerations in Confirmatory Subgroup Analyses

Advanced IPD meta-analysis methods for observational studies

Reflection paper on assessment of cardiovascular safety profile of medicinal products

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)

Analyzing Teacher Professional Standards as Latent Factors of Assessment Data: The Case of Teacher Test-English in Saudi Arabia

Study Design. Svetlana Yampolskaya, Ph.D. Summer 2013

Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases

Clinical trial design issues and options for the study of rare diseases

Lecture 2. Key Concepts in Clinical Research

BIOSTATISTICAL METHODS

Bayesian hierarchical modelling

Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration

Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome

Using principal stratification to address post-randomization events: A case study. Baldur Magnusson, Advanced Exploratory Analytics PSI Webinar

RANDOMIZATION. Outline of Talk

Analyzing diastolic and systolic blood pressure individually or jointly?

Examining Relationships Least-squares regression. Sections 2.3

SISCR Module 7 Part I: Introduction Basic Concepts for Binary Biomarkers (Classifiers) and Continuous Biomarkers

Version No. 7 Date: July Please send comments or suggestions on this glossary to

Transcription:

Selection and estimation in exploratory subgroup analyses a proposal Gerd Rosenkranz, Novartis Pharma AG, Basel, Switzerland EMA Workshop, London, 07-Nov-2014

Purpose of this presentation Proposal for exploratory subgroup analyses Favoring estimation over tests and/or p-values Identification of subgroups with differing efficacy ( predictive subgroups ) as an integral part of analysis Accounting for subgroup selection uncertainty and selection bias Discussion of properties, limitations and extensions General remark: The potential of any method of subgroup analysis is limited by the information content of the data 2 EMA Workshop GR 07-Nov-2014 Exploratory subgroup analysis

Definition of Subgroups Draft EMA Guideline on Subgroups in confirmatory trials, Section 4.1 A subgroup can be defined as any subset of the recruited patient population that fall into the same category (level) with regard to one or more descriptive factors prior to randomization Factors may relate to Demographic characterstics (e.g., age, gender, race) Disease characteristics (e.g., time of diagnosis, severity) Clinical considerations (e.g., region, concomitant medication) Subgroups defined by different factors may overlap Sufficient to consider subgroups based on a single factor in most cases 3 EMA Workshop GR 07-Nov-2014 Exploratory subgroup analysis

Consistency Evidence for lack of consistency if at least one subgroup can be identified where the effect of test treatment over control differs from the overall effect or, equivalently, between subgroup and its complement How to identify subgroups without too much risk of chance findings or incorrect selections? How to estimate the effect in the identified subgroups without too much bias? What constitutes sufficient evidence of consistency is less obvious 4 EMA Workshop GR 07-Nov-2014 Exploratory subgroup analysis

A modeling approach for subgroup identification Assume subgroups can be defined in terms of factors with two levels, that is, each factor divides the patient population into two subgroups like Gender: male, female Age group: 65y, > 65y List of candidate factors available Turn subgroup identification into model selection For each candidate factor, fit a statistical model including a term that reflects the amount by which the difference in treatment arms is influenced by the factor Select the model providing the best fit and estimate the amount by which the difference in treatment arms is influenced by the factor 5 EMA Workshop GR 07-Nov-2014 Exploratory subgroup analysis

A modeling approach for subgroup identification Drawbacks Does not account for model selection uncertainty May result in biased estimates (driven by search for the best fit) Small changes of data may result in substantially different results Better but expensive approach: Identify factor corresponding to best fit in a series of studies Note how often different factors are identified Aggregate estimates across studies Consider re-sampling instead 6 EMA Workshop GR 07-Nov-2014 Exploratory subgroup analysis

A modeling approach for subgroup identification 1. Sample with replacement (by treatment) from original data 2. Identify model with best fit to sample 3. Obtain estimates from that model 4. Repeat steps 1 3 above many times 5. Select the factor belonging to the most frequently selected model ( voting ) 6. Obtain (biased-reduced) parameter estimates for that selection from the samples 7 EMA Workshop GR 07-Nov-2014 Exploratory subgroup analysis

Simulations Assumptions Normally distributed data with σ = 1 Overall difference between test and control: 0.5 90% power, α = 0.00125 (two trials in one) 1:1 randomization 166 subjects per treatment Two predictive factors: gender and age group, such that each gender age group combination accounts for 25% of subjects Three unpredictive factors called random1, random2, random3 that mark subgroups randomly Effect of control = 0 (regardless of subgroups) Effect of test treatment in subgroups on following slides 500 simulated studies with 200 re-samples each 8 EMA Workshop GR 07-Nov-2014 Exploratory subgroup analysis

Simulation results Consistent effects Consistent mean effect of test treatment Age group Factor Frequency of selection (%) Gender Marginal Difference 0 1 0 0.5 0.5 0.5 1 0.5 0.5 0.5 Marginal 0.5 0.5 0.5 Difference 0.0 True marginal difference Estimator Bias-reduced estimator Age group 21.0 0.0-0.02(0.35) -0.02(0.25) Gender 18.0 0.0-0.06(0.29) -0.05(0.21) Random 1 19.8 0.0 0.07(0.34) 0.04(0.21) Random 2 19.0 0.0 0.02(0.38) 0.02(0.27) Random 3 22.2 0.0 0.01(0.40) 0.02(0.28) 0.0 9 EMA Workshop GR 07-Nov-2014 Exploratory subgroup analysis

Simulation results Inconsistent effects Inconsistent mean effect of test treatment Age group Factor Frequency of selection (%) Gender Marginal Difference 0 1 0 0.2 0.4 0.3 1 0.5 0.9 0.7 Marginal 0.35 0.65 0.5 Difference 0.3 True marginal difference Estimate Bias-reduced estimate Disease status 61.6 0.4 0.48(0.21) 0.41(0.21) Gender 27.0 0.3 0.45(0.25) 0.37(0.23) Random 1 3.8 0.0-0.03(0.45) -0.01(0.35) Random 2 2.8 0.0-0.15(0.39) -0.12(0.30) Random 3 4.8 0.0 0.03(0.55) 0.02(0.42) 0.4 10 EMA Workshop GR 07-Nov-2014 Exploratory subgroup analysis

Remarks Approach can be extended to Binary and (ordered) categorical endpoints Continuous factors (covariates) Need to account for subgroups defined by more than one factor if effect in a subgroup strongly affected by another factor: 11 EMA Workshop GR 07-Nov-2014 Exploratory subgroup analysis

Outlook Proposed method can be further extended to derive a predictor for the effect of treatment in a future patient Can use the factor values directly no need to artificially dichotomize numerical factors (like age, BMI) to define subgroups with all its disadvantages Predicted effect size under alternative treatments and measure of prediction uncertainty can support physician s decision on how to treat a patient 12 EMA Workshop GR 07-Nov-2014 Exploratory subgroup analysis